“…As EBV is present in 50% of HLs 20 and is known to induce fascin expression, we analyzed EBV expression in all 10 cases of LyP associated with systemic lymphomas. Lack of expression of EBV in LyP and cutaneous ALCL has previously been reported 21–23 . Consistent with these data, we found no evidence of EBV infection in LyP cases associated with HL, neither in the skin lesions nor in the lymph nodes.…”
This is the first study to demonstrate that fascin is expressed in cutaneous CD30+ LPD and that it is a candidate marker of disease progression in LyP.
“…As EBV is present in 50% of HLs 20 and is known to induce fascin expression, we analyzed EBV expression in all 10 cases of LyP associated with systemic lymphomas. Lack of expression of EBV in LyP and cutaneous ALCL has previously been reported 21–23 . Consistent with these data, we found no evidence of EBV infection in LyP cases associated with HL, neither in the skin lesions nor in the lymph nodes.…”
This is the first study to demonstrate that fascin is expressed in cutaneous CD30+ LPD and that it is a candidate marker of disease progression in LyP.
“…Therefore, in immunosuppressed individuals, EBV may play an important role in the development of CD30 + ALCL. 2 The EB viral genome has been demonstrated in primary cutaneous CD30 + ALCL related to acquired immunodeficiency syndrome by in situ hybridization in a study by Carbone et al ; 4 however, in that study, the EBV positivity may have been related more to immunosuppression than to the type of lymphoma. Second, it has been suggested that EBV is associated with CD30 + ALCL of the B-cell type, because EBV was detected in six of 17 cases of CD30 + ALCL of the B-cell type.…”
Section: Discussionmentioning
confidence: 92%
“…Given the similarities, the association of CD30 + lymphoproliferative disorders with EBV was suspected. 2 Indeed, some investigators have reported cutaneous 3,4 and systemic [5][6][7] CD30 + ALCL associated with EBV. However, the majority do not support this association because EBV has not been found in either CD30 + ALCL or LyP.…”
Section: Introductionmentioning
confidence: 99%
“…However, the majority do not support this association because EBV has not been found in either CD30 + ALCL or LyP. 2,[8][9][10][11][12][13] Therefore, the association of CD30 + lymphoproliferative disorders with EBV still remains unclear.…”
Background Epstein-Barr virus (EBV)-associated cutaneous lymphoproliferative disorders are prevalent in Asia, and less frequent in Western countries. Aim To elucidate the possible association of EBV with CD30 + anaplastic large cell lymphoma (ALCL) involving the skin and lymphomatoid papulosis (LyP) in South Korea.
MethodsIn situ hybridization for EBV-encoded small RNA (EBER) and immunohistochemistry including viral latent membrane protein-1 (LMP-1) were performed on formalin-fixed, paraffin-embedded skin specimens of 26 cases of LyP and 16 cases of CD30 + ALCL involving the skin which were selected from six university hospital medical centers in South Korea.
Results
Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease.CD30+ LPDs comprise approximately 25%-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T-cell neoplasm of the skin behind mycosis fungoides. Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis, and more aggressive hematolymphoid neoplasms.
K E Y W O R D SCD30+ lymphoproliferative disorder, primary cutaneous anaplastic large cell lymphoma
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.